News | May 23, 2024
Merck to acquire life science company Mirus Bio for US$ 600 million
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
CMOs showed an increasing reluctance to take on debt in 2022
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Subscribe To Our Newsletter & Stay Updated
